Literature DB >> 23623666

Microparticles in atrial fibrillation: a link between cell activation or apoptosis, tissue remodelling and thrombogenicity.

L Jesel1, M Abbas, F Toti, A Cohen, T Arentz, O Morel.   

Abstract

Microparticles (MPs) are small membrane vesicles that are shed from virtually all cells in response to stress. Widely described in atherothrombotic diseases, recent data suggest a role for circulating MPs in the hypercoagulable state associated with supraventricular tachyarrhythmia. During atrial fibrillation, several mechanisms, such as high ventricular heart rate, low or oscillatory shear stress, stretch, hypoxia, inflammation and oxidative stress, are potent inducers of apoptotic cell death, which leads to the shedding of procoagulant MPs within the vasculature. As key regulators of cell-cell cross-talk and important mediators of inflammatory, thrombogenic and proteolytic pathways, MPs directly or indirectly contribute to the amplification loops involved in atrial fibrillation. Because high levels of platelets and endothelial-derived MPs are identified during stroke and are associated with infarct size and clinical outcome, they are proposed to be a potent marker of ischaemic risk. During pulmonary vein isolation, the additional increases of platelet and leukocyte MP levels suggest the extent of tissue damage and reflect a transient activation of the coagulation cascade that could favour ischaemic stroke. Conversely, the observed decreases of several apoptotic markers some months after the restoration of sinus rhythm suggest that the extent of apoptotic processes is reversible and might enable restoration of haemostasis. In this review, we will summarise the current evidence supporting the roles of apoptosis and cell activation in the development of the prothrombotic state observed in atrial fibrillation, with a particular focus on procoagulant MPs.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Endothelium; Leukocytes; Platelet; Pulmonary vein isolation; Stroke; Thrombosis

Mesh:

Year:  2013        PMID: 23623666     DOI: 10.1016/j.ijcard.2013.03.031

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  20 in total

1.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

2.  Connexins and Atrial Fibrillation in Obstructive Sleep Apnea.

Authors:  Abdelnaby Khalyfa; David Gozal
Journal:  Curr Sleep Med Rep       Date:  2018-10-26

3.  Does an imbalance in circulating vascular endothelial growth factors (VEGFs) cause atrial fibrillation in patients with valvular heart disease?

Authors:  Keke Wang; Yanyan Liu; Suiqing Huang; Huayang Li; Jian Hou; Jiaxing Huang; Jiantao Chen; Kangni Feng; Mengya Liang; Guangxian Chen; Zhongkai Wu
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

4.  Increased Levels of Platelets and Endothelial-Derived Microparticles in Patients With Non-Valvular Atrial Fibrillation During Rivaroxaban Therapy.

Authors:  Aleksandra Lenart-Migdalska; Leszek Drabik; Magdalena Kaźnica-Wiatr; Lidia Tomkiewicz-Pająk; Piotr Podolec; Maria Olszowska
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

5.  Comparison of Immature Platelet Fraction and Factors Associated with Inflammation, Thrombosis and Platelet Reactivity Between Left and Right Atria in Patients with Atrial Fibrillation.

Authors:  Olga Perelshtein Brezinov; Ziv Sevilya; Ella Yahud; Michael Rahkovich; Yonatan Kogan; Gergana Marincheva; Yana Kakzanov; Eli Lev; Avishag Laish-Farkash
Journal:  J Atr Fibrillation       Date:  2021-02-28

6.  Prognostic implications and procoagulant activity of phosphatidylserine exposure of blood cells and microparticles in patients with atrial fibrillation treated with pulmonary vein isolation.

Authors:  Huan Meng; Junjie Kou; Ruishuang Ma; Wenbo Ding; Yan Kou; Muhua Cao; Zengxiang Dong; Yayan Bi; Hemant S Thatte; Jialan Shi
Journal:  Mol Med Rep       Date:  2017-10-11       Impact factor: 2.952

Review 7.  Exosomes in atrial fibrillation: therapeutic potential and role as clinical biomarkers.

Authors:  Kun Xiang; Muhammad Akram; Walaa Fikry Elbossaty; Jinfu Yang; Chengming Fan
Journal:  Heart Fail Rev       Date:  2021-07-12       Impact factor: 4.654

8.  Circulating endothelial-derived apoptotic microparticles in the patients with ischemic symptomatic chronic heart failure: relevance of pro-inflammatory activation and outcomes.

Authors:  Alexander E Berezin; Alexander A Kremzer; Tatayna A Samura; Yulia V Martovitskaya
Journal:  Int Cardiovasc Res J       Date:  2014-09-01

9.  Associations of MMP-2, BAX, and Bcl-2 mRNA and Protein Expressions with Development of Atrial Fibrillation.

Authors:  Shu-Ling Diao; Hui-Pu Xu; Bei Zhang; Bao-Xin Ma; Xian-Liang Liu
Journal:  Med Sci Monit       Date:  2016-05-04

10.  Relationship between renal function and circulating microparticles, soluble P-selectin and E-selectin levels in atrial fibrillation.

Authors:  Yee Cheng Lau; Qinmei Xiong; Andrew D Blann; Gregory Y H Lip
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.